Dr. Gurleen Kour
Scientist
Pharmacology Division
CSIR – Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Email: gurleen[dot]kour[at]iiim[dot]res[dot]in
Bio Sketch
Dr.Kour has worked on the preclinical drug development including the in vitro and in vivo assessment of ADME and pharmacokinetic properties for lead selection and lead optimization. In the area of Inflammation Pharmacology she has exploredthe combination of natural anti-inflammatory agents with first-line disease modifying anti-rheumatic drug (DMARDs) to improve the efficacy of therapy and reduce the incidence of hepatotoxicity in the treatment of rheumatoid arthritis. Furthermore, she is also involved in exploiting the potential of natural compounds as anti-diabetic and anti-obesity agents.Her current research focus is to develop natural product driven drug candidates in the area of rheumatoid arthritis, diabetes mellitus and obesity.
Education
Degree | Subjects | University | Qualifying Year |
Postdoctorate | Life Sciences | University of Jammu | 2022 |
Ph.D | Biological Sciences | CSIR- Indian Institute of Integrative Medicine | 2018 |
B. Tech | Industrial Biotechnology | Shri Mata Vaishno Devi University | 2012 |
Position Held
Position Held | Period | Organization |
Scientist | July 2022 to Present | CSIR-IIIM, Jammu |
DBT- Senior Research Associate | Jan 2022- July 2022 | University of Jammu |
DBT- Research Associate | Jan 2020-Dec 2021 | University of Jammu |
Area of Expertise
- Screening of natural compounds and derivatives for anti-inflammatory, anti-rheumatic and anti-obesity potential.
- Proficiency in preclinical drug development including the in vitro and in vivo assessment of ADME and pharmacokinetic properties.
- In vitro assessment of physicochemical parameters including solubility, lipophilicity, permeability PAMPA and plasma stability.
- Permeability assessment and P-gp mediated efflux in Caco-2 cell culture model.
- Hepatic metabolic stability and cytotoxicity assessment.
- Drug-drug interaction including CYP450 inhibition profiling.
- In vivo pharmacokinetic analysis and bioavailability.
Projects
Mechanism based rational strategies for efficient administration of bergenin and investigation of its combination with leflunomide to improve efficacy of therapy in rheumatoid arthritis (PI, DBT)
Publications
Authors | Title | Journal |
Kour G, Haq SA, Bajaj BK, Gupta PN, Ahmed Z. | Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends.
|
Pharmacological Research. 2021,169:105618.
Impact Factor: 10.3 |
Kour G, Choudhary R, Anjum S, Bhagat A, Bajaj BK, Ahmed Z. | Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future? | Biochemical Pharmacology. 2022, 197:114929.
Impact factor: 6.1 |
Kour G, Singh PP, Bhagat A, Ahmed Z. | Biopharmaceutic parameters, pharmacokinetics, transport and CYP mediated drug interactions of IIIM-017: A novel nitroimidazooxazoleanalogue with anti-tuberculosis activity. | European Journal of Pharmaceutical Sciences. 2017; 106: 71–78.
Impact Factor: 5.1 |
Kour G, Chandan BK, Khullar M, Munagala G, Singh PP, Bhagat A, Gupta AP, Vishwakarma RA, Ahmed Z. | Development and validation of a highly sensitive LCMS/MS-ESI method for quantification of IIIM-019-A novel nitroimidazole derivative with promising action against Tuberculosis: Application to drug development. | Journal of Pharmaceutical and Biomedical Analysis. 2016; 124: 26-33.
Impact Factor: 3.5 |
Kour G, Kumar A, Singh PP, Sharma S, Bhagat A, Vishwakarma RA, Ahmed Z. | Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 – A potential oral treatment for tuberculosis. | Pulmonary Pharmacology and Therapeutics. 2016; 40: 44-51.
Impact Factor: 3.4 |
Kour G, Haq SA, Ahmed Z, Gupta P.N.
|
BookChapter title: Novel delivery systems for natural products in improved therapy of rheumatoid arthritis. Book title: Role and application of novel drug delivery system for phytoconstituents. | CRC Press, 2022
|
Yempalla KR, Munagala G, Singh S, Kour G, Sharma S, Chib R, Kumar S, Wazir P, Singh GD, Raina S, Bharate SS, Khan IA, Vishwakarma RA, Singh PP. | Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents. | ACS Med. Chem. Lett. 2015; 6 (10): 1059-64.
Impact Factor: 4.6
|
Awards and Honours
- Associate Member of the Society of Inflammation Research, India.
- Post-Doctorate Fellowship by the Department of Biotechnology Research Associate (DBT-RA) program in Biotechnology and Life Sciences, Govt. of India (2019)
- Senior Research Fellowship (GATE-SRF) from Council of Scientific and Industrial Research (CSIR), GOI (2014-2017)
- Junior Research Fellowship (GATE-JRF) from Council of Scientific Industrial Research (CSIR), GOI, 2012-2014
- Qualified Jammu and Kashmir State Eligibility Test (JK SET/SLET) in Life Sciences
- QualifiedAll-India Level Examination, Graduate Aptitude Test in Engineering (GATE) in Biotechnology.
- Speaker at International conference: 4th Annual Congress on Drug Discovery & Designing, Bangkok, Thailand, July 03-04, 2017.
- Second Prize in Poster presentation,Indo-US Symposium on Botanical Drug development, Medanta-The Medicity, Gurgaon, India, December 13-14th, 2013.
Students
NIL